Effects of beta-blocking drugs in alcohol withdrawal: a double-blind comparative study with propranolol and diazepam

Bailly, D.; Servant, Dominique; Blandin, N; Beuscart, R.; Parquet, P. J.

doi:10.1016/0753-3322(92)90047-b

Cited by 31 publications

(14 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, prazosin decreases drinking and stress-induced alcohol craving in alcoholics (Fox et al, 2012; Simpson et al, 2009) and reduces voluntary ethanol consumption in rodent models of anxiety-related drinking (Rasmussen et al, 2009; Verplaetse et al, 2012; Walker et al, 2008). Similarly, β1/2-AR antagonists have been used clinically to treat anxiety associated with alcohol withdrawal (Bailly et al, 1992; Sellers et al, 1977), and decrease operant responding for ethanol in a rodent model of dependence (Gilpin and Koob, 2010). SNRIs have shown promise in reducing anxiety-related alcohol intake, reportedly lessening alcohol craving and anxiety following withdrawal in clinical populations (Kim et al, 2005; Liappas et al, 2005; Petrakis et al, 2012) and likewise attenuating anxiety-like behavior, ethanol drinking and the symptoms of acute withdrawal in rodents (Ji et al, 2008; Mochizuki et al, 2002; Saglam et al, 2004; Simon O’Brien et al, 2011).…”

Section: Discussionmentioning

confidence: 99%

Adolescent social isolation increases anxiety-like behavior and ethanol intake and impairs fear extinction in adulthood: Possible role of disrupted noradrenergic signaling

et al. 2015

View full text Add to dashboard Cite

Alcohol use disorder, anxiety disorders, and post-traumatic stress disorder (PTSD) are highly comorbid, and exposure to chronic stress during adolescence may increase the incidence of these conditions in adulthood. Efforts to identify the common stress-related mechanisms driving these disorders have been hampered, in part, by a lack of reliable preclinical models that replicate their comorbid symptomatology. Prior work by us, and others, has shown that adolescent social isolation increases anxiety-like behaviors and voluntary ethanol consumption in adult male Long-Evans rats. Here we examined whether social isolation also produces deficiencies in extinction of conditioned fear, a hallmark symptom of PTSD. Additionally, as disrupted noradrenergic signaling may contribute to alcoholism, we examined the effect of anxiolytic medications that target noradrenergic signaling on ethanol intake following adolescent social isolation. Our results confirm and extend previous findings that adolescent social isolation increases anxiety-like behavior and enhances ethanol intake and preference in adulthood. Additionally, social isolation is associated with a significant deficit in the extinction of conditioned fear and a marked increase in the ability of noradrenergic therapeutics to decrease ethanol intake. These results suggest that adolescent social isolation not only leads to persistent increases in anxiety-like behaviors and ethanol consumption, but also disrupts fear extinction, and as such may be a useful preclinical model of stress-related psychopathology. Our data also suggest that disrupted noradrenergic signaling may contribute to escalated ethanol drinking following social isolation, thus further highlighting the potential utility of noradrenergic therapeutics in treating the deleterious behavioral sequelae associated with early life stress.

show abstract

Section: Discussionmentioning

confidence: 99%

Adolescent social isolation increases anxiety-like behavior and ethanol intake and impairs fear extinction in adulthood: Possible role of disrupted noradrenergic signaling

et al. 2015

View full text Add to dashboard Cite

show abstract

“…), and has been used clinically to treat anxiety associated with alcohol withdrawal (Bailly et al. ). Propranolol also controls some of the clinical signs of withdrawal (Carlsson and Johansson ; Zilm et al.…”

Section: Discussionmentioning

confidence: 99%

“…; Bailly et al. ), and also decrease operant responding for ethanol in ethanol‐dependent rats (Gilpin and Koob ). Serotonin and norepinephrine reuptake inhibitors (SNRIs) have also shown promise in reducing anxiety‐related alcohol intake, reportedly lessening alcohol craving and anxiety following withdrawal in clinical populations (Liappas et al.…”

Section: Introductionmentioning

confidence: 99%

Chronic treatment with prazosin or duloxetine lessens concurrent anxiety‐like behavior and alcohol intake: evidence of disrupted noradrenergic signaling in anxiety‐related alcohol use

Skelly

Weiner

2014

Brain and Behavior

View full text Add to dashboard Cite

BackgroundAlcohol use disorders have been linked to increased anxiety, and enhanced central noradrenergic signaling may partly explain this relationship. Pharmacological interventions believed to reduce the excitatory effects of norepinephrine have proven effective in attenuating ethanol intake in alcoholics as well as in rodent models of ethanol dependence. However, most preclinical investigations into the effectiveness of these drugs in decreasing ethanol intake have been limited to acute observations, and none have concurrently assessed their anxiolytic effects. The purpose of these studies was to examine the long-term effectiveness of pharmacological interventions presumed to decrease norepinephrine signaling on concomitant ethanol self-administration and anxiety-like behavior in adult rats with relatively high levels of antecedent anxiety-like behavior.MethodsAdult male Long-Evans rats self-administered ethanol on an intermittent access schedule for eight to ten weeks prior to being implanted with osmotic minipumps containing either an a1-adrenoreceptor antagonist (prazosin, 1.5 mg/kg/day), a β1/2-adrenoreceptor antagonist (propranolol, 2.5 mg/kg/day), a serotonin/norepinephrine reuptake inhibitor (duloxetine, 1.5 mg/kg/day) or vehicle (10% dimethyl sulfoxide). These drugs were continuously delivered across four weeks, during which animals continued to have intermittent access to ethanol. Anxiety-like behavior was assessed on the elevated plus maze before treatment and again near the end of the drug delivery period.ResultsOur results indicate that chronic treatment with a low dose of prazosin or duloxetine significantly decreases ethanol self-administration (P < 0.05). Furthermore, this decrease in drinking is accompanied by significant reductions in the expression of anxiety-like behavior (P < 0.05).ConclusionsThese findings suggest that chronic treatment with putative inhibitors of central noradrenergic signaling may attenuate ethanol intake via a reduction in anxiety-like behavior.

show abstract

“…In humans, propranolol and other b-adrenergic antagonists have been shown to reduce anxiety provoked by stressful situations (Liu et al, 1991;Dyck and Chung, 1991;Laverdure and Boulenger, 1991) or drug withdrawal (Bailly et al, 1992). These compounds are primarily effective in reducing moderate, but not extreme, autonomic somatic symptoms of anxiety (Tyrer, 1988).…”

Section: Predictive Validitymentioning

confidence: 98%

Recent advances in animal models of chronic antidepressant effects: The novelty-induced hypophagia test

Dulawa

Hen

2005

Neuroscience & Biobehavioral Reviews

376

296

View full text Add to dashboard Cite

Effects of beta-blocking drugs in alcohol withdrawal: a double-blind comparative study with propranolol and diazepam

Cited by 31 publications

References 14 publications

Adolescent social isolation increases anxiety-like behavior and ethanol intake and impairs fear extinction in adulthood: Possible role of disrupted noradrenergic signaling

Adolescent social isolation increases anxiety-like behavior and ethanol intake and impairs fear extinction in adulthood: Possible role of disrupted noradrenergic signaling

Chronic treatment with prazosin or duloxetine lessens concurrent anxiety‐like behavior and alcohol intake: evidence of disrupted noradrenergic signaling in anxiety‐related alcohol use

Recent advances in animal models of chronic antidepressant effects: The novelty-induced hypophagia test

Contact Info

Product

Resources

About